Tracing the origin of psychosis in schizophrenia - A repetitive TMS/neuroimaging study of frontostriatal interactio

Completed

Conditions: schizophrenia
10039628

Registration Number: NL-OMON37137

Lead Sponsor: niversitair Medisch Centrum Utrecht

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 168

Inclusion Criteria

All subjects:
- Right-handedness
- Written informed consent;Specific for schizophrenia patients:
- DSM-IV diagnosis of schizophrenia
- Age between 18 and 45;Specific for healthy siblings of patients with schizophrenia:
- Age between 30 and 45;Specific for healthy volunteers:
- Age between 18 and 45

Exclusion Criteria

All subjects:
- Ferrous objects in or around the body (e.g. braces, glasses, pacemaker, metal fragments)
- Drug or alcohol abuse over a period of six months prior to the experiment
- History of closed- or open-head injury
- History of neurological illness or endocrinological dysfunction
- Claustrofobia
- Major medical history
- Chronic use of medication
- History of epilepsy
- History of epilepsy in first-degree relatives
- Incapability of giving an informed consent
- Symptoms indicative of schizophrenia;Specific for women:
- Pregnancy;Specific for healthy siblings of patients with schizophrenia:
- History of psychiatric illness;Specific for healthy volunteers:
- History of psychiatric illness
- First-degree family member with psychiatric illness

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter is brain activity in the frontostriatal system, as<br /><br>measured with functional magnetic resonance imaging.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary study parameters associated with task performance (reaction time,<br /><br>accuracy), structural MRI (number of white matter fibers between areas,<br /><br>white-matter integrity), repetitive TMS (intensity of stimulation) and<br /><br>abnormalities in candidate genes for dopamine receptors.</p><br>